← All trials
NCT06124495
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 13, 2023
- Primary completion
- Feb 13, 2023
- Completion date
- Feb 13, 2023
- First posted
- Nov 9, 2023
- Last posted
- Nov 9, 2023
- Enrollment
- 58
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Galenicum HealthLead sponsor
- Avant Santé Research Center S.A. de C.VOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.